Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $276.51.

  • Zhengye Biotechnology Holding's Short-term Investments changed N/A to $276.51 in Q2 2025 from the same period last year, while for Jun 2025 it was $276.51, marking a year-over-year change of. This contributed to the annual value of $278.34 for FY2024, which is 9998.38% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Short-term Investments stood at $276.51.
  • Zhengye Biotechnology Holding's 5-year Short-term Investments high stood at $1.7 million for Q4 2023, and its period low was $276.51 during Q2 2025.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Short-term Investments value was $278.43 (recorded in 2024), while the average stood at $560966.0.
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Short-term Investments was 9998.34% (2024), while the steepest drop was 9998.34% (2024).
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Short-term Investments stood at $1.7 million in 2023, then plummeted by 99.98% to $278.43 in 2024, then decreased by 0.69% to $276.51 in 2025.
  • Its Short-term Investments stands at $276.51 for Q2 2025, versus $278.43 for Q4 2024 and $1.7 million for Q4 2023.